Noxopharm is an Australian-based drug development company with offices in Melbourne and Sydney. It intends to focus on two areas of drug technology. The first is the potential benefit to cancer patients in being able to overturn resistance to standard of care chemotherapies and radiotherapies. NOX66 is the first pipeline drug candidate, with later generation drug candidates under investigation in an R&D program.

The second area relates to drug-delivery technology behind NOX66 and the opportunity it offers to exploit the broader therapeutic opportunities of isoflavonoid compounds.

Media Releases

Latest Company News


Aug 2018 10:30 AM
Noxopharm (ASX:NOX) update on ..
20 Aug 2018 - Noxopharm Limited (ASX:NOX) Managing Director and CEO Dr Graham Kelly discusses the company’s focus on the proposed use of NOX66 as a radio-enhancer in radiotherapy cancer treatment.

Contact Information